WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Friday, March 29, 2024 
Add Press Release News | News Feeds Feeds | Email This News Email


Covid-19 vaccination campaign safety : France rolls out the "Medication Shield" of Synapse Medicine
Saturday, January 23, 2021

BORDEAUX, France, Jan. 15, 2021 /PRNewswire/ -- Synapse Medicine, which was founded by public health physicians, rolls out its Medication Shield technology to increase the safety of the COVID-19 vaccination campaign in France, in collaboration with the regional pharmacovigilance centers (CRPVs) and the French National Agency for Medicines and Health Products Safety (ANSM). This technology comes out as a valuable time-saver, supporting the management of adverse drug reaction (ADR) reports by making it easier and allowing pharmacovigilance teams to focus their attention on the most severe cases. Because COVID-19 vaccines were developed in a brief period of time, it is crucial to ensure rigor and responsiveness in monitoring any possible side-effects.

The Medication Shield: a unique technology to improve adverse drug events monitoring

In France, monitoring the safety of drugs, particularly vaccines, is carried out by the ANSM and the CRPVs. Synapse Medicine has been working in collaboration with these health institutions for the past 18 months on a research project aiming to support the management of pharmacovigilance cases. This technology, called "Medication Shield", manages ADR reports in real-time (declared on the online reporting portal by the general public), encodes them automatically into an international classification (MedDRA), and ranks them by severity. The ANSM has chosen to deploy the Medication Shield on a national level in response to the current context, which requires reinforced pharmacovigilance and important responsiveness regarding COVID-19 vaccines. This technology allows monitoring teams from the ANSM and the CRPVs to analyze ADR reports more rapidly, depending on their severity.

Artificial Intelligence to improve the pharmacovigilance of the COVID-19 vaccines

The COVID-19 vaccines were brought to the public quickly thanks to innovative development processes. This requires official health authorities to strengthen their protection systems against medication risks and to rapidly deploy increased pharmacovigilance systems.

"The Medication Shield acts as a collective shield. It allows pharmacovigilance experts, physicians, and pharmacists to save time during the management of ADR reports and focus their attention on the most severe cases. The major challenge here is to monitor any unexpected events following the COVID-19 vaccination in real-time , and more broadly following the use of any medication," comments Dr. Clément Goehrs, co-founder and CEO of Synapse Medicine.

About Synapse Medicine

Synapse Medicine's (https://synapse-medicine.com) mission is to provide access to reliable and useful drug information. The start-up, which collaborates with some of the most significant French University Hospitals, has developed a Medication Intelligence platform dedicated to improve medication use. A reference in its category, its solution is 100% independent and is now used by thousands of healthcare professionals and patients.

Press Contact:
presse@synapse-medicine.com

Logo - https://mma.prnewswire.com/media/1198589/synapse_medicine_Logo.jpg

View original content to download multimedia:http://www.prnewswire.com/news-releases/covid-19-vaccination-campaign-safety--france-rolls-out-the-medication-shield-of-synapse-medicine-301208651.html

SOURCE Synapse Medicine



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav JND eDiscovery Receives National Law Journal Hall of Fame Award in Two Categories | Mar 29, 2024
Nav Trip.com's Global 3.3 Promotion Sees Record Success in Asia and Europe | Mar 29, 2024
Nav Europe Fibercos and Towercos Market Dynamics Report 2024: Lessons Learned and Key Takeaways for Telcos and Infrastructure Companies | Mar 29, 2024
Nav China Non-Invasive Prenatal Testing Analysis Report 2024: Testing Volume 2018-2032 and Market Estimation Forecasts 2024-2032 with Focus on Mergers & Acquisitions, Collaborations, and Partnerships | Mar 29, 2024
Nav Global Highly Potent API (Active Pharmaceutical Ingredient) Industry Research 2023-2033: Advancements in Containment Technologies, and Increasing Investment for Manufacturing Units | Mar 29, 2024
Nav Exclusive Networks announces a major step in its growth strategy in APAC with NEXTGEN Group acquisition | Mar 29, 2024
Nav United States Self-Monitoring Blood Glucose Devices Market Research 2023-2032: SMBG Devices and CGM Systems Surge - The Shift from Traditional Blood Glucose Meters | Mar 29, 2024
Nav "Bleach: Brave Souls" Thousand-Year Blood War Zenith Summons: Reinforcements Featuring Meninas, Rangiku, and Yumichika Begins March 31 Alongside a Spring Festival Campaign | Mar 29, 2024
Nav Evolution enters Delaware through Rush Street Interactive | Mar 29, 2024
Nav IDTechEx Discusses the Sustainability of Electric Vehicle Fire Protection Materials | Mar 29, 2024
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News